肺表面活性剂治疗新生儿呼吸窘迫综合征的临床疗效

Clinical effect of pulmonary surfactant in treating neonatal respiratory distress syndrome

目的:探讨肺表面活性剂(PS)治疗新生儿呼吸窘迫综合征(RDS)的临床疗效。方法:将60例RDS患儿分为PS加呼吸机治疗组(37例)和呼吸机治疗组(23例),比较两组患儿存活率、病死率、RDS合并症的发生率。结果:PS加呼吸机治疗组和呼吸机治疗组RDS患儿的存活率分别为89.2%、34.2%(P<0.05);死亡率分别为10.8%、65.2%(P<0.05);两组RDS合并症的比较:肺出血(PH)发生率(8.1%、30.4%)和脑室内出血(IVH)发生率(5.4%、26%)比较有显著性差异(均P<0.05),气胸和动脉导管未闭发生率比较两组无显著性差异(P>0.05)。结论:PS能够提高RDS患儿存活率,降低其死亡率,显著减少合并症PH和IVH的发生,临床疗效显著。

Objective：To explore the clinical effect of the pulmonary surfaetant （PS）in treating neonatal respiratory distress syndrome （RDS）.Methods：Sixty RDS newborns were divided into two groups,one group （37 cases） were treated with PS（curosurf）combining with ventilator and another group（23 cases）were treated mainly ventilator.The survival rate, mortality and the morbidity of the complications of RDS were respectively compared between the two groups.Results：The survival rate of the group were treated with PS combining with ventilator and the group were treated mainly with ventilator was 89.2% and 34.2%,respectively （P〈0.05）.The mortality of the two groups was 10.8% and 65.2%（P〈0.05）.There were significant difference between the morbidity of pulmonary hemorrhage （8.1% and 30.4%, respectively,P〈0.05）and intracerebral ventricular hemorrhage （5.4% and 26% ,P〈0.05）of the two groups,but no significant difference between that of pneumothorax and patent ductus arteriosus.Conclusion：PS has significantly efficacy in treating RDS newborn which could improve the survival rate,reduce the mortality and decrease the morbidity of the complications of RDS.